Logo image
Validation of an improved competitive enzyme-linked immunosorbent assay to detect Equine arteritis virus antibody
Journal article   Open access   Peer reviewed

Validation of an improved competitive enzyme-linked immunosorbent assay to detect Equine arteritis virus antibody

Chungwon Chung, Carey Wilson, Peter Timoney, Udeni Balasuriya, Ethan Adams, D. Scott Adams, James F Evermann, Alfonso Clavijo, Kathleen Shuck, Sandy Rodgers, …
Journal of veterinary diagnostic investigation, Vol.25(6), pp.727-735
11/2013
Handle:
https://hdl.handle.net/2376/114075
PMID: 24202992
pdf
chung-et-al-2013515.56 kBDownloadView
Open Access
url
https://doi.org/10.1177/1040638713508401View
Published (Version of record) Open

Abstract

Equine arteritis virus assay validation competitive enzyme-linked immunosorbent assay serum neutralization Antibody
The objective of the present study was to validate a previously described competitive enzyme-linked immunosorbent assay (cELISA) to detect antibody to Equine arteritis virus (EAV) based on GP5-specific nonneutralizing monoclonal antibody (mAb) 17B79 using the World Organization for Animal Health (OIE)–recommended protocol, which includes the following 5 in-house analyses. 1) The assay was calibrated with the OIE-designated reference serum panel for EAV; 2) repeatability was evaluated within and between assay runs; 3) analytical specificity was evaluated using sera specific to related viruses; 4) analytical sensitivity was evaluated with sera from horses vaccinated with an EAV modified live virus (MLV) vaccine; and 5) the duration of cELISA antibody detection following EAV vaccination was determined. The positive cELISA cutoff of ≥35% inhibition (%I) was confirmed by receiver operating characteristic plot analysis. Analytical sensitivity of the cELISA was comparable to the serum neutralization (SN) assay in that it detected EAV-specific antibody as early as 8 days postvaccination. The duration of EAV-specific antibody detected by cELISA was over 5 years after the last vaccination. This cELISA could detect EAV-specific antibody in serum samples collected from horses infected with various EAV strains. In the field trial performed by American Association of Veterinary Laboratory Diagnosticians–accredited state laboratories and OIE laboratory, the diagnostic specificity of the cELISA was 99.5% and the diagnostic sensitivity was 98.2%. The data using various serum panels also had consistently significant positive correlation between SN titers and cELISA %I results. The results further confirm that the EAV antibody cELISA is a reliable, simple alternative to the SN assay for detecting EAV-specific antibodies in equine sera.

Metrics

28 Record Views

Details

Logo image